Pustaka:

1. Summary of Product Characteristics

a) Cefotaxime injection, Genus Pharmaceuticals. Date of partial revision of text 23 July 2008
b) Cefotaxime injection, Wockhardt UK Ltd. Date of first authorisation 13 October 2007 (2g), 16 October 2007 (500mg & 1g)
c) Cefotaxime sodium injection (Bowmed (ACS Dobfar Generics)). Date of revision of text 20 October 2009
d) Cefotaxime sodium, Lupin (Europe) Ltd. Date of renewal of authorisation 16 February 2010
2. Trissel "Handbook on injectable drugs" 15th Edition p287
3. Hammersmith Hospitals Intravenous Medicine Administration Guide November 2004
4. UCL Hospitals Injectable Medicines Administration Guide 2nd edition
5. Mallikarjuna, D., Tippa, R., Singh, N., & Pradesh, U. (2010). Cefotaxime sodium for injection reconstitution stability study in intravenous
and intramuscular diluents, 1(2), 113121.
6. Summary of Product Characteristics
a) Kefadim (Flyn Pharma), last revised 01/06/2005
b) Ceftazidime 1g and 2g for injection (Wockhardt), last revised July 2011
c) Fortum for injection, GlaxoSmithKline, last revised September 2012
d) Ceftazidime for injection (Sandoz Ltd), last revised 9/4/2011
e) Ceftazidime 3g powder for solution for infusion (Stragen UK Ltd), last revised 28/02/2008
f) Ceftazidime 500mg, 1g and 2g powder for solution for injection, (MAH: Villerton Invest SA, distributed by Bowmed Ibisqus Ltd) last
revised 31/10/2011
g) Ceftazidime 500mg, 1g and 2g powder for solution for injection, Fresenius Kabi, last revised 06/04/2009
7. The UK Injectable Medicines Guide Produces by NHS Lothian Medicines Information Service (July 2013) Pharmacy Department
8. Summary of Product Characteristics
a) Roche, last updated 07/07/2010
b) Wockhardt UK Ltd, last updated 02/12/2010
c) Lupin, last updated 31/03/2010
d) Villerton, distributed by Bowmed Ibisqus Ltd, last updated 31/10/2011
e) Stravencon, last updated 31/10/2011
9. British National Formulary No. 63, March 2012
10. Medicines for Children produced by the Royal College of Paediatric & Child Health 2003 6a) British National Formulary for Children
2011-2012
11. Mallikarjuna, D., Tippa, R., Singh, N., & Pradesh, U. (2010). Reconstitution Stability of Ceftriaxone Sodium for Injection in, 1(2), 2430.

12. Summary of Product Characteristics

a) Sulperazone, Pfizer, last update 17 September 2009
b) Cegava, Biocon
13. AllenI.V. Beyond-use dates and stability indication assay methods in pharmaceutical compounding. Secundum Artem. 2009.
14. USP 27. Chapter 795. Stability criteria and beyond use date.
15. Handbook of Injectable Drug, 15th ed, Lawrence A Tressel.
16. Guideline The UK Injectable Medicines Guide, Juli 2013.
17. Mc Graw Hills, IV Drug Handbook, 2009
18. Das Gupta V, Stewart KR, Nohria S.,Stability of vancomycin hydrochloride in 5% dextrose and 0.9% sodium chloride injections, Am J
Hosp Pharm. 1986 Jul;43(7):1729-31
19. Scull, P.D., 2009, McGraw-Hills; IV Drug Handbook, McGraw-Hill Companies Inc., New York
20. Departemen Kesehatan RI, 2009, Pedoman Pencampuran Obat Suntik dan Penanganan Sediaan Sitostatika
21. Schull, Patricia Dwyer.2009.Mcgraw-Hill's I.V. Drug Handbook, p. 128, p. 430, p. 412
22. USP.2006.Cefobid (Sterile cefoperazone) Pfizer Roerig (Division of Pfizer Inc, NY, NY 10017
23. Markham, Ontario.2008.Product Monograph Mycamine.Astellas Pharma Canada, Inc
24. Mycamine: EPHAR-European Medicines Agency Europa (online) diakses tanggal 3 Februari 2015 (
25. Pfizer.2013.Flagyl (Metronidazole Hydrochloride) 500 mg for injection, sterile. G.D. Searle (Division of Pfizer Inc, NY, NY 10017
26. Kemenkes Malaysia.2000. Monograf Ubat 157 Cefoperazone.
27. www.globalrph.com
28. www.drugs.com
29. www.elephantcare.org
30. www.mhra.gov.uk
31. www.dailymed.com
32. www.medscape.com